ABBVIE
A Study to Assess Real-World Use, Safety, and Effectiveness of Oral Upadacitinib in Adult and Adolescent (>=12 Years Old) Participants With Atopic Dermatitis
- Conditions
- First Posted Date
- 2021-10-18
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 873
- Registration Number
- NCT05081557
- Locations
- 🇷🇺
National Research Center Institute of Immunology of the FMBA of Russia /ID# 245221, Moscow, Moskva, Russian Federation
🇷🇺LLC Medical Center ABC of Health /ID# 244816, Kazan, Tatarstan, Respublika, Russian Federation
🇦🇷Hospital Universitario Austral /ID# 241607, Pilar, Buenos Aires, Argentina
Study to Evaluate Symptoms of Exocrine Pancreatic Insufficiency in Adult Participants With Cystic Fibrosis or Chronic Pancreatitis Treated With Creon
- First Posted Date
- 2021-10-06
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 30
- Registration Number
- NCT05069597
- Locations
- 🇺🇸
Valley Children's Hospital /ID# 231452, Madera, California, United States
🇺🇸Cleveland Clinic Main Campus /ID# 245864, Cleveland, Ohio, United States
🇺🇸Asr, Llc /Id# 239566, Nampa, Idaho, United States
A Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Intravenous (IV) Infusion and Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Crohn's Disease
- First Posted Date
- 2021-10-05
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 176
- Registration Number
- NCT05068284
- Locations
- 🇺🇸
Southern California Res. Ctr. /ID# 233512, Coronado, California, United States
🇺🇸Hoag Memorial Hosp Presbyterian /ID# 233555, Irvine, California, United States
🇺🇸University of Colorado Hospital /ID# 239361, Aurora, Colorado, United States
A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to Severe Psoriasis
- First Posted Date
- 2021-09-14
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 156
- Registration Number
- NCT05044234
- Locations
- 🇺🇸
West Virginia Research /ID# 238517, Morgantown, West Virginia, United States
🇺🇸Lenus Research & Medical Group /ID# 238695, Sweetwater, Florida, United States
🇯🇵Mie University Hospital /ID# 239275, Tsu-shi, Mie, Japan
Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers (PICCOLO)
- Conditions
- Interventions
- First Posted Date
- 2021-09-13
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 79
- Registration Number
- NCT05041257
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸The University of Alabama at Birmingham - Division of Gynecology Oncology O'Neal Comprehensive Cancer Center, Birmingham, Alabama, United States
🇺🇸Alaska Women's Cancer Care/Providence Alaska Medical Center, Anchorage, Alaska, United States
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab
- Conditions
- Interventions
- First Posted Date
- 2021-09-01
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 500
- Registration Number
- NCT05029882
- Locations
- 🇺🇸
NEXT Oncology /ID# 231578, San Antonio, Texas, United States
🇫🇷Centre Antoine-Lacassagne /ID# 231730, Nice, Provence-Alpes-Cote-d Azur, France
🇺🇸University of California, Los Angeles /ID# 243841, Los Angeles, California, United States
A Study to Evaluate Adverse Events and Change in Disease State of Oral Upadacitinib in Adolescent Participants Ages 12 to <18 Years Old Diagnosed With Atopic Dermatitis (AD)
- Conditions
- First Posted Date
- 2021-09-01
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 170
- Registration Number
- NCT05029895
- Locations
- 🇯🇵
Kobe City Medical Center General Hospital /ID# 250836, Kobe-shi, Hyogo, Japan
🇯🇵Hosui General Medical Clinic /ID# 241881, Sapporo-shi, Hokkaido, Japan
🇯🇵Takeoka Dermatology Clinic /ID# 240610, Marugame, Kagawa, Japan
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine
- First Posted Date
- 2021-08-31
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 775
- Registration Number
- NCT05028569
- Locations
- 🇺🇸
Albuquerque Clinical Trials, Inc. /ID# 231101, Albuquerque, New Mexico, United States
🇺🇸Duplicate_University Of Cincinnati Medical Center /ID# 231739, Cincinnati, Ohio, United States
🇨🇿Fakultní Nemocnice U Sv. Anny V Brně /ID# 232213, Brno, Brno-mesto, Czechia
A Study to Assess Patient-Reported Quality of Life and Effectiveness on Control of Bleeding in Adult Participants With Heavy Menstrual Bleeding Due to Uterine Fibroids Taking Oral Oriahnn Capsules
- Conditions
- First Posted Date
- 2021-08-30
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 23
- Registration Number
- NCT05026502
- Locations
- 🇺🇸
IQVIA RDS, Inc., Durham, North Carolina, United States
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Budigalimab
- Conditions
- Interventions
- First Posted Date
- 2021-08-13
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 268
- Registration Number
- NCT05005403
- Locations
- 🇺🇸
University of Illinois at Chicago /ID# 251750, Chicago, Illinois, United States
🇺🇸Fort Wayne Medical Oncology and Hematology, Inc /ID# 232593, Fort Wayne, Indiana, United States
🇺🇸Community Health Network, Inc. /ID# 243011, Indianapolis, Indiana, United States